

Informazione Regolamentata n. 20106-8-2023	Data/Ora Ricezione 08 Febbraio 2023 19:48:56	Euronext Star Milan
---	---	----------------------------

Societa' : PHARMANUTRA
Identificativo : 172317
Informazione
Regolamentata
Nome utilizzatore : PHARMANUTRAN01 - Sarti
Tipologia : REGEM
Data/Ora Ricezione : 08 Febbraio 2023 19:48:56
Data/Ora Inizio : 08 Febbraio 2023 19:49:01
Diffusione presunta
Oggetto : PR PHARMANUTRA SPA - PHN
HYPERCAR FERRARI

<i>Testo del comunicato</i>

Vedi allegato.

PHARMANUTRA S.P.A PARTNERS WITH FERRARI TO FACE THE CHALLENGES OF THE NEW LE MANS HYPERCAR 499P

The Italian company will be present with its Cetilar® brand on the Ferrari 499P prototype with which the world-famous car manufacturer will compete in the FIA World Endurance Championship and the 24 Hours of Le Mans

Pisa, 8 February 2023 – [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specialised in mineral and iron-based nutritional supplements and medical devices for muscles and joints, is ready to face the great challenge of the FIA World Endurance Championship (WEC) alongside Team Ferrari-AF Corse, which will be competing with two official Ferrari 499P prototypes.

Under the agreement, the Cetilar® brand, a line of products containing Cetylated Fatty Acids for healthy muscles and joints, available as Cream, Patch, Tape and now also Oro, will feature on the two new Le Mans Hypercar category cars, which will make their début at Sebring, Florida (USA), in March, for the first race of the World Endurance Championship. However, PharmaNutra's involvement will not stop there. Cetilar® will also appear on the suits of the six official Ferrari drivers at the wheel of the two Prancing Horse Hypercars.

"The Ferrari challenge in the new Le Mans Hypercar prototype class, is one of the most eagerly awaited of the whole of 2023, and not just in the motor sports sector. And PharmaNutra, I am proud to point out, has believed in this project from day one, when it was still at an embryonic stage, supporting it every step of the way with passion and great dedication," stated **Roberto Lacorte**, Deputy Chairman of the company established in 2003 with his brother Andrea. *"A partnership, moreover, that will not merely consist in the presence of our Cetilar® brand on the magnificent Ferrari 499P and on the drivers' suits, but also in a close medical and scientific partnership with Med-Ex, the sector leader that has worked with Ferrari for many years".*

As the official Medical Partner of Ferrari Competizioni GT, Med-Ex will attend to the physical preparation and all aspects of the health of the Prancing Horse's official drivers participating in the FIA WEC behind the wheel of the 499P, and the rest of the team, using Cetilar® products, in the run-up to the launch of the new sports nutrition line, and the other nutritional supplements in which Sucrosomial® Technology ensures better tolerability and outstanding absorption levels.

This is the confirmation of a fully comprehensive relationship between world-renowned ambassadors of Italian manufacturing, that does not stop with the presence of the brand alone, but goes much further, as part of a close partnership and exchange of expertise.

“Ours is a real, concrete involvement, in line with the many sports partnerships we are currently involved in. We feel close to the Ferrari world and are thrilled to have the chance to make our contribution in a challenge that has been eagerly awaited for years and will usher in a new era in motor sports”, summed up **Lacorte**, who plays a hands-on role in racing activities as a driver in the all-Italian Cetilar Racing team, which is competing in the IMSA WeatherTech SportsCar Championship with a Ferrari 296 GT3 under the technical management of AF Corse.

“The ideal bond between Cetilar® and the project involving Ferrari-AF Corse’s team with the 499P is, in many ways, almost natural. Cetilar is a market-leading product developed by PharmaNutra, a symbol of Italian excellence in the pharma and healthcare field, and the same excellence inspires the partnership between Ferrari and our team in the Le Mans Hypercar project”, explained **Amato Ferrari**, founder and Team Principal of AF Corse. *“We are proud to be able to rely on a partner of this standing that has supported the project right from the start, and that has believed in the values of Ferrari and AF Corse for many years, as our joint commitment with Cetilar Racing in the world’s most prestigious endurance racing events demonstrates”.*

The programme of the FIA World Endurance Championship in which the new Ferrari 499P will be competing will make its track début in Sebring (USA) for the Championship’s official prologue (11-12 March). This will be followed by the first race, again in Sebring, on 17 March, and legs in Portimão (Portugal, 16 April), Spa (Belgium, 29 April), Monza (9 July), Fuji (Japan, 10 September) and Bahrain (4 November), which will take place either side of the most important event of the year, the legendary 24 Hours of Le Mans, scheduled for the weekend of the 10 and 11 June.

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Deputy Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique food supplements and innovative nutrition devices by carrying out the entire production process, from the proprietary starting materials through to the finished product. The effectiveness of its products is demonstrated by a wealth of scientific evidence, including 135 publications involving more than 7000 subjects. The Group distributes and places its products on the market in Italy and abroad. Within Italy, sales activities are carried out through a network of over 160 medical science liaisons serving the medical profession, as well as focusing on the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales activities are guaranteed abroad in 70 different countries through 47 partners chosen amongst the best pharmaceutical companies. PharmaNutra is a market leader in the manufacture of dietary supplements containing iron with its SiderAL® brand, where it boasts important patents covering its Sucrosomial® Technology. Over the years, the Group has developed a precise strategy regarding the management and production of intellectual property, based on integrated management of all the various components: proprietary starting materials, patents, brands and clinical evidence.

PharmaNutra.it

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa, Italy

Tel. +39 050-7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan, Italy

Tel. +39 02-83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com

Fine Comunicato n.20106-8

Numero di Pagine: 5